BD Diagnostics, a segment of BD (Becton, Dickinson and Company), a leading global medical technology company, announced today at EUROGIN 2013 that the Company has achieved CE/IVD marking of its BD Totalys(TM) MultiProcessor, an automated instrument that integrates the pre-processing for the BD SurePath(TM) Liquid-based Pap Test with a molecular aliquot, maintaining sample integrity while improving efficiency in the lab. The Company also supported a symposium at the conference which highlighted the performance of the new BD Onclarity(TM) HPV Assay on the BD Viper(TM) LT System, which is pending EU certification.
"These new products are part of BD's integrated Women's Health portfolio and support full sample chain of custody, high diagnostic accuracy and a clear patient management approach - all important elements to improving patient care," said Paul Holt, Global Market Segment Leader, Women's Health & Cancer - BD Diagnostics. "When laboratories and physicians partner with BD Diagnostics, they benefit from highly customized, leading-edge solutions for the rapidly changing landscape of cervical cancer screening."